Buysschaert, Martin
[UCL]
Bobbioni, E
Starkie, M
Frith, L
AIM: The aim of this study was to investigate the effectiveness of troglitazone (a peroxisome proliferator-activated receptor-gamma agonist developed primarily for the treatment of Type 2 diabetes mellitus (DM)), 100 or 200mg/day, in terms of glycaemic control, lipid profile and tolerability, when given in addition to existing sulphonylurea therapy. METHODS: A 16-week, randomized, parallel-group placebo-controlled trial in 259 Type 2 diabetic patients already on sulphonylurea therapy. RESULTS: At week 16, adjusted geometric mean HbA1c with troglitazone 100mg (7.7%; P=0.023) and 200mg (7.4%; P<0.001) was lower with sulphonylurea alone (8.2%). At all weeks, adjusted geometric mean fasting serum glucose levels were lower in both troglitazone groups, compared with sulphonylurea alone (P=0.007 to P<0.001). At week 16, both troglitazone groups showed reductions in immune reactive insulin compared with sulphonylurea alone (200mg, 13%; P=0.032: 100mg, 5%; NS). Troglitazone reduced serum levels of nonesterified fatty acids at week 16 (100 g, 12%; P=0.042) and at all weeks (200mg, 17-24%; P=0.014 to P<0.001). The incidence of drug-related adverse events was similar in all groups (23-24% of patients). There was no apparent association between hypoglycaemia and the addition of troglitazone to sulphonylurea therapy. CONCLUSIONS: Troglitazone 100 or 200 mg added to usual sulphonylurea therapy in patients with Type 2 DM is associated with a significant improvement in glycaemic control, without altering the adverse-event profile of the sulphonylurea.
- Alberti Kgmm, Diabetic Med., 11, 899 (1994)
- Hermann L. S., Biguanides and Sulfonylureas as Combination Therapy in NIDDM, 10.2337/diacare.13.3.37
- Kumar S., Boulton A. J. M., Beck-Nielsen H., Berthezene F., Muggeo M., Persson B., Spinas G. A., Donoghue S., Lettis S., Stewart-Long P., Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients, 10.1007/s001250050498
- Leutenegger Marc, Sacca Luigi, Alderton Claire, Eckland David, Lettis Sally, Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non—insulin-dependent diabetes mellitus, 10.1016/s0011-393x(97)80031-8
- Schwartz Sherwyn, Raskin Philip, Fonseca Vivian, Graveline Jane F., Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus, 10.1056/nejm199803263381302
- Inzucchi Silvio E., Maggs David G., Spollett Geralyn R., Page Stephanie L., Rife Frances S., Walton Veronika, Shulman Gerald I., Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus, 10.1056/nejm199803263381303
- Fujiwara T, Diabetes., 37, 1549 (1988)
- Fujiwara T, Metabolism., 44, 486 (1995)
- Levin K, Endocrinol Metab., 4, 255 (1997)
- Lehmann S., Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrP^C, in Cultured Cells, 10.1074/jbc.270.50.30221
- Lenhard James M, Kliewer Steven A, Paulik Mark A, Plunket Kelli D, Lehmann Jurgen M, Weiel James E, Effects of troglitazone and metformin on glucose and lipid metabolism, 10.1016/s0006-2952(97)00229-3
- Groop LC., Diabetes Care., 15, 737 (1992)
- 13 MA Young, Dja Eckland, R Eastmond, and S. Lettis Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.Ann Med.; 1998 , 1998 , 1998 .
- Ghazzi M, Diabetes., 46 (1997)
- Correa Jcn, Eur J Clin Res., 9, 151 (1997)
Bibliographic reference |
Buysschaert, Martin ; Bobbioni, E ; Starkie, M ; Frith, L. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.. In: Diabetic medicine : a journal of the British Diabetic Association, Vol. 16, no. 2, p. 147-53 (1999) |
Permanent URL |
http://hdl.handle.net/2078.1/8267 |